JP2024506041A5 - - Google Patents

Info

Publication number
JP2024506041A5
JP2024506041A5 JP2023547694A JP2023547694A JP2024506041A5 JP 2024506041 A5 JP2024506041 A5 JP 2024506041A5 JP 2023547694 A JP2023547694 A JP 2023547694A JP 2023547694 A JP2023547694 A JP 2023547694A JP 2024506041 A5 JP2024506041 A5 JP 2024506041A5
Authority
JP
Japan
Prior art keywords
dose
pharmaceutical composition
composition according
administration period
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023547694A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506041A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/053030 external-priority patent/WO2022167690A1/en
Publication of JP2024506041A publication Critical patent/JP2024506041A/ja
Publication of JP2024506041A5 publication Critical patent/JP2024506041A5/ja
Pending legal-status Critical Current

Links

JP2023547694A 2021-02-08 2022-02-08 潰瘍性大腸炎を予防、処置、または改善するためのアミセリモド Pending JP2024506041A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163147060P 2021-02-08 2021-02-08
US63/147,060 2021-02-08
PCT/EP2022/053030 WO2022167690A1 (en) 2021-02-08 2022-02-08 Amiselimod for preventing, treating, or ameliorating ulcerative colitis

Publications (2)

Publication Number Publication Date
JP2024506041A JP2024506041A (ja) 2024-02-08
JP2024506041A5 true JP2024506041A5 (cg-RX-API-DMAC7.html) 2025-02-14

Family

ID=80447376

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023547694A Pending JP2024506041A (ja) 2021-02-08 2022-02-08 潰瘍性大腸炎を予防、処置、または改善するためのアミセリモド

Country Status (9)

Country Link
US (1) US20240299318A1 (cg-RX-API-DMAC7.html)
EP (1) EP4288041A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024506041A (cg-RX-API-DMAC7.html)
CN (1) CN116940350A (cg-RX-API-DMAC7.html)
AU (1) AU2022217475A1 (cg-RX-API-DMAC7.html)
CA (1) CA3207440A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023009249A (cg-RX-API-DMAC7.html)
TW (1) TW202245742A (cg-RX-API-DMAC7.html)
WO (1) WO2022167690A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025134072A1 (en) * 2023-12-21 2025-06-26 Bausch Health Ireland Limited Methods for preventing, treating, or ameliorating ulcerative colitis in certain patient populations with amiselimod

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
RU2433117C2 (ru) 2005-12-15 2011-11-10 Мицубиси Танабе Фарма Корпорейшн Аминное соединение и его применение в медицинских целях
MX367667B (es) 2008-12-22 2019-08-30 Novartis Ag Régimen de dosificación de un agonista de los receptores de s1p.
MA40775A (fr) * 2014-10-01 2017-08-08 Respivert Ltd Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38
CA3002540C (en) * 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
US20180228778A1 (en) * 2015-08-11 2018-08-16 Akaal Pharma Pty Ltd Compositions comprising s1p receptor modulators
WO2018237379A2 (en) * 2017-06-23 2018-12-27 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
TWI721483B (zh) * 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
CN113613640B (zh) * 2018-09-08 2024-11-29 谭文 肾上腺素能β2受体激动剂R-对映体在治疗炎症性肠病及其肠外疾病的新应用
US20220390464A1 (en) * 2019-07-30 2022-12-08 Children's Medical Center Corporation Methods and compositions for characterizing inflammatory bowel disease

Similar Documents

Publication Publication Date Title
US3795739A (en) Treatment of parkinson disease
JP2023041862A5 (cg-RX-API-DMAC7.html)
JP6117845B2 (ja) ニタゾキサニドの制御放出医薬配合物
JP2024540183A5 (cg-RX-API-DMAC7.html)
CA2393437A1 (en) Exo-s-mecamylamine formulation and use in treatment
JP2024069192A5 (cg-RX-API-DMAC7.html)
JP2024075655A5 (ja) 鏡像異性体的に純粋なブプロピオンの医薬の製造における使用
JP2022544711A5 (cg-RX-API-DMAC7.html)
JP2018507243A5 (cg-RX-API-DMAC7.html)
JP2006513184A5 (cg-RX-API-DMAC7.html)
US20200188309A1 (en) Delayed release deferiprone tablets and methods of using the same
JP2025508004A5 (cg-RX-API-DMAC7.html)
KR20240032789A (ko) 시클로-히스프로를 유효성분으로 포함하는 비만 예방 또는 치료용 약제학적 조성물
JP2023537921A5 (cg-RX-API-DMAC7.html)
MX2024010637A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
JP2025148449A5 (cg-RX-API-DMAC7.html)
JP2016505050A5 (cg-RX-API-DMAC7.html)
JP2022553888A5 (cg-RX-API-DMAC7.html)
JP2022512158A5 (cg-RX-API-DMAC7.html)
JP2024540439A5 (cg-RX-API-DMAC7.html)
JP2022177119A5 (cg-RX-API-DMAC7.html)
JP2019533672A5 (cg-RX-API-DMAC7.html)
JP2024531799A5 (cg-RX-API-DMAC7.html)
JP2024501235A5 (cg-RX-API-DMAC7.html)
JP2021530568A5 (cg-RX-API-DMAC7.html)